Preliminary results of the Phase IIa trial of a folate binding protein (FBP) adjuvant cancer vaccine (E39+GM-CSF) in ovarian and endometrial cancer patients to prevent recurrence
نویسندگان
چکیده
Background FBP (aka Folate Receptor-a) is an immunogenic protein that is over-expressed in breast, endometrial (EC) and ovarian cancer (OC). FBP expression in malignant cells is 20-80 fold higher compared to the limited distribution in normal cells. We have completed enrollment of a Phase IIa clinical trial with E39, an HLA-A2 restricted, FBP peptide vaccine + GM-CSF. The vaccine is administered in the adjuvant setting to prevent recurrences in high-risk, EC and OC patients (pts) rendered clinically disease-free with standard-of-care therapy. Here, we summarize preliminary toxicity (tox), immunologic and clinical response to vaccination.
منابع مشابه
Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients
BACKGROUND Folate binding protein(FBP) is an immunogenic protein over-expressed in endometrial(EC) and ovarian cancer(OC). We are conducting a phase I/IIa trial of E39 (GALE 301)+GM-CSF, an HLA-A2-restricted, FBP-derived peptide vaccine to prevent recurrences in disease-free EC and OC patients. This interim analysis summarizes toxicity, immunologic responses, and clinical outcomes to date. ME...
متن کاملPreliminary results for the phase 1 trial of a folate receptor alpha adjuvant cancer vaccine in ovarian and endometrial cancer patients
Background Folate Receptor Alpha (FRa) is an immunogenic protein that is over-expressed in breast, endometrial and ovarian cancer (OC). In fact, FRa expression in malignant cells is 20-fold higher compared to normal cells. We have begun a phase 1 clinical trial with E39, an HLA-A2 restricted, FRa peptide vaccine. The vaccine is administered in the adjuvant setting to prevent recurrences in high...
متن کاملVaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers.
The immune system can be efficiently stimulated and targeted to specific antigens expressed exclusively or preferentially by experimental cancers. The foremost limitations to extending this vaccine technology to the prevalent epithelial-derived cancers are the lack of: (a) identified tumor-associated antigens recognized by cellular immunity; (b) antigens expressed on the majority of tumor cells...
متن کاملIn vivo Characterization of Fusion Protein Comprising of A1 Subunit of Shiga Toxin and Human GM-CSF: Assessment of Its Immunogenicity and Toxicity
Background: Most cancer cells become resistant to anti-cancer agents. In the last few years, a new approach for targeted therapy of human cancer has been developed using immunotoxins which comprise both the cell targeting and the cell killing moieties. Methods: In the present study, the recombinant Shiga toxin A1 subunit fused to human granulocyte-macrophage colony stimulating factor (A1-GM-CSF...
متن کاملEvaluation of pre-treatment serum levels of IL-7 and GM-CSF in colorectal cancer patients
Background: Survival of Colorectal cancer (CRC) patients is considerably stage-dependent therefore, early diagnosis is a pivotal factor in decreasing mortality and morbidity associated with this cancer. GM-CSF and IL-7 are reported to increase in different cancers and we aim to investigate the pre-treatment serum levels of GM-CSF and IL-7 in Iranian patients with colorectal cancer. Methods: ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 2 شماره
صفحات -
تاریخ انتشار 2014